Travera

Travera is a private, early-stage diagnostics company founded in 2018 and based in Cambridge, MA. It has developed a novel functional precision oncology platform that measures changes in cancer cell mass (Mass Response Testing, MRT) in response to drug exposure, enabling a rapid 2-day turnaround for therapy guidance. The company is currently generating early clinical evidence through studies with major U.S. cancer centers and is in a pre-revenue, early-access commercial phase. Its core value proposition is speed and broad applicability, offering an alternative or complement to genomic-based testing.

Mass Response Testing (MRT): A proprietary microfluidic platform that measures real-time changes in the mass of single live cancer cells in response to drug exposure, enabling rapid ex vivo prediction of drug efficacy.

Travera competes in the functional precision oncology space against companies using high-content imaging, organoid, or AI-driven platforms (e.g., Recursion, Exscientia's patient-centric AI). It also competes indirectly with comprehensive genomic profiling firms (e.g., Foundation Medicine, Guardant Health). Travera's primary differentiator is its claimed 2-day turnaround time, which is significantly faster than most functional assays that take weeks.